Z. Liu and F. Wang Pages 1487 - 1505 ( 19 )
The cell adhesion molecule integrin α<sub>v</sub>β<sub>3</sub> is an important player in the process of angiogenesis. In the last decades, a series of radiolabeled Arg-Gly-Asp (RGD) peptides targeting integrin α<sub>v</sub>β<sub>3</sub> has been prepared and optimized for positron emission tomography (PET) and single-photon-emission computed tomography (SPECT) imaging of integrin α<sub>v</sub>β<sub>3</sub> expression. Several promising radiotracers have been tested in clinical trials. In this review, we will introduce strategies that have been used to optimize and accelerate RGD radiotracers towards clinical translation; illustrate RGD-based radiotracers that have been investigated in clinical trials; and discuss the other applications of RGD radiotracers aside from tumor detection.
Arg-Gly-Asp (RGD), integrin α<sub>v</sub>β<sub>3</sub>, molecular imaging, radionuclide therapy, radiotracer, tumor.
, (Z. Liu) Medical Isotopes Research Center, Peking University, 38 Xueyuan Road, Beijing 100191, China.